According to published clinical evidence (a randomized, double-blind, placebo-controlled clinical trial, published in Diabetes Metabolism Research and Reviews) CuraLin is a safe and effective add-on therapy to first-line oral antidiabetes drugs in patients with diagnosed Type-2 Diabetes, especially in cases where those fail to achieve adequate glycemic control.
CuraLin is produced in Europe and in the US, in FDA registered and GMP facilities.
CuraLin is already present in 22 countries globally and is used by over 100k people worldwide.
|Categories||Branded Finished Products; Plant-based Products|
|Sales markets||Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa|
|Supplied from||Latvia; United States|
|Product Applications||Dietary Supplements; Food Supplements|
|Product Certifications||Halal; Health & Safety (GMP, HAACP and equivalents); Natural; Organic; Traceable|